{"id":327029,"date":"2026-10-26T16:47:41","date_gmt":"2026-10-26T11:17:41","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=327029"},"modified":"2026-10-26T16:47:41","modified_gmt":"2026-10-26T11:17:41","slug":"active-ingredients-and-custom-synthesis-leader-branded-generics-innovator-and-portable-molecular-testing-company-stocks-roadmap-summit-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-synthesis-leader-branded-generics-innovator-and-portable-molecular-testing-company-stocks-roadmap-summit-list\/","title":{"rendered":"3 Active Ingredients and Custom Synthesis Leader, Branded Generics Innovator and Portable Molecular Testing Company Stocks With a Strong Future Roadmap: Divi’s Laboratories, Glenmark Pharmaceuticals and Molbio Diagnostics"},"content":{"rendered":"

Divi’s Laboratories, Glenmark Pharmaceuticals and Molbio Diagnostics: ROE of 14.2% to 28.1% and FY22 to FY26 revenue CAGR of 5.1% to 16.8%. Prices as of 23 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The three API, branded generics and Truenat testing stocks to watch are Divi’s Laboratories, Glenmark Pharmaceuticals and Molbio Diagnostics. Their return on equity ranges from 14.2% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 16.8%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while Molbio Diagnostics has the fastest revenue growth at 16.8% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n

API, branded generics and Truenat testing stocks offer a focused view of a sector where demand keeps widening. Divi’s Laboratories, Glenmark Pharmaceuticals and Molbio Diagnostics cover an active ingredients and custom synthesis leader, a branded generics innovator and a portable molecular testing company.<\/p>\n

This list covers three API, branded generics and Truenat testing stocks with complete current figures: Divi’s Laboratories, Glenmark Pharmaceuticals and Molbio Diagnostics. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n